Workflow
Zhengchuan Pharmapack(603976)
icon
Search documents
【干货】中硼硅玻璃产业链全景梳理及区域热力地图
Qian Zhan Wang· 2025-08-18 07:16
Core Insights - The Chinese borosilicate glass industry is primarily focused on the midstream manufacturing segment, with key applications in medical institutions and pharmaceutical logistics [1][2]. Industry Overview - The upstream raw materials for the borosilicate glass industry include quartz sand, borax, cullet, calcite, and feldspar, with major production equipment being muffle furnaces and draw machines [1]. - Key upstream suppliers include quartz sand leader Quartz Corporation and international institutions like Corning for glass raw materials [2]. Regional Distribution - The borosilicate glass industry is concentrated in the eastern coastal regions of China, particularly in Jiangsu Province, indicating a regional heat map of production [6]. Company Performance - In 2024, Shandong Pharmaceutical Glass and Zhengchuan Co. have nearly 100% sales rates, while Linuo Pharmaceutical's sales rate is below 90% [8]. - Shandong Pharmaceutical Glass has a high overall business gross margin, while Linuo Pharmaceutical and Zhengchuan Co. have gross margins around 22%-23% [8]. Company Developments - Shandong Pharmaceutical Glass plans to achieve an annual production capacity of 2.4-2.5 billion borosilicate molded bottles by mid-2025, with an expected total capacity exceeding 5 billion by the end of 2025 [10]. - Linuo Pharmaceutical announced the acquisition of a 51% stake in an Egyptian pharmaceutical glass manufacturer, aiming to establish a production base in North Africa [10]. - Qibin Group is set to start trial production of two 50 tons/day borosilicate pharmaceutical glass tube production lines in Luzhou, Sichuan, by October 2024 [10]. - Weigao Co. aims to increase its pre-filled syringe production capacity from 800 million units in 2023 to 1.2 billion units by 2025, targeting a global market share of 35% [10]. - Zhengchuan Co. plans to launch a 300 million unit pre-filled syringe production line in early 2025, with a second phase project to start by the end of 2025 [10].
正川股份收盘上涨1.92%,滚动市盈率76.42倍,总市值32.95亿元
Sou Hu Cai Jing· 2025-08-15 12:16
Core Viewpoint - Zhengchuan Co., Ltd. has a closing price of 21.79 yuan, with a rolling PE ratio of 76.42 times, indicating a higher valuation compared to the industry average [1] Company Summary - Zhengchuan Co., Ltd. specializes in the research, production, and sales of pharmaceutical packaging materials, including borosilicate glass tubes and pre-filled syringes [1] - The company is a member of the China Pharmaceutical Packaging Association and the National Packaging Standardization Technical Committee [1] - As of March 31, 2025, the number of shareholders is 18,803, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Financial Performance - In the first quarter of 2025, the company reported revenue of 162 million yuan, a year-on-year decrease of 34.24%, and a net profit of 10.91 million yuan, down 48.15% year-on-year [1] - The sales gross margin for the same period is 21.61% [1] Industry Summary - The average PE ratio for the medical device industry is 56.58 times, with a median of 39.97 times, placing Zhengchuan Co., Ltd. at the 96th position in the industry ranking [1][2] - The industry includes various companies with lower PE ratios, such as Jiuan Medical at 11.36 times and Yuyue Medical at 20.20 times [2]
正川股份收盘下跌3.30%,滚动市盈率74.98倍,总市值32.33亿元
Sou Hu Cai Jing· 2025-08-14 13:21
Company Overview - Zhengchuan Co., Ltd. closed at 21.38 yuan, down 3.30%, with a rolling PE ratio of 74.98 times and a total market value of 3.233 billion yuan [1] - The company specializes in the research, production, and sales of pharmaceutical packaging materials, including borosilicate glass tubes and sodium-calcium glass tubes [1] - Zhengchuan is a member of the China Pharmaceutical Packaging Association and the National Packaging Standardization Technical Committee [1] Financial Performance - For Q1 2025, the company reported revenue of 162 million yuan, a year-on-year decrease of 34.24%, and a net profit of 10.9141 million yuan, down 48.15% year-on-year [1] - The sales gross margin for the latest quarter was 21.61% [1] Shareholder Information - As of March 31, 2025, the number of shareholders was 18,803, a decrease of 638 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, placing Zhengchuan at the 96th position in the industry ranking [1][2] - The industry average market value is 11.792 billion yuan, while the median is 5.679 billion yuan [2]
正川股份收盘下跌1.85%,滚动市盈率78.24倍,总市值33.73亿元
Sou Hu Cai Jing· 2025-08-12 10:52
Company Overview - Zhengchuan Co., Ltd. closed at 22.31 yuan, down 1.85%, with a rolling PE ratio of 78.24 times and a total market value of 3.373 billion yuan [1] - The company operates in the pharmaceutical packaging materials sector, focusing on the research, production, and sales of medicinal glass tubes and other packaging materials [1] - Main products include borosilicate glass tubes, soda-lime glass tubes, aluminum caps, pre-filled syringes, and cassette bottles [1] Financial Performance - For Q1 2025, the company reported revenue of 162 million yuan, a year-on-year decrease of 34.24%, and a net profit of 10.9141 million yuan, down 48.15% year-on-year, with a gross margin of 21.61% [1] Shareholder Information - As of March 31, 2025, the number of shareholders was 18,803, a decrease of 638 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical device industry is 57.51 times, with a median of 41.25 times, placing Zhengchuan Co., Ltd. at the 96th position in the industry ranking [1][2] - Other companies in the industry have varying PE ratios, with the highest being 21.19 times for Antu Biology and the lowest at 11.26 times for Jiuan Medical [2]
2025年中国中硼硅玻璃关联评审现状 “A”类评审结果占优【组图】
Qian Zhan Wang· 2025-08-12 09:27
转自:前瞻产业研究院 行业主要上市公司:力诺药包(301188.SZ)、山东药玻(600529.SH)、旗滨集团(601636.SH)、威高股份 (01066.HK)、正川股份(603976.SH)等 本文核心数据:产量;销量 2、"A"类与"I"类评审结果数量相当 1、关联评审流程 截至2025年,中国中硼硅玻璃包材"A"类与"I"类评审结果分布中,"A"类数量239个,占比47%,"I"类占 比53%。 最新修订的《中华人民共和国药品管理法》进一步明确规定:国务院药品监督管理部门在审批药品时, 对化学原料药一并审评审批,对相关辅料、直接接触药品的包装材料和容器一并审评,对药品的质量标 准、生产工艺、标签和说明书一并核准。原辅包登记平台上的"与制剂共同审评审批结果"标识改为两 种,即"A"和"I","A"代表已批准在上市制剂使用的原料/辅料/包材,"I"代表尚未通过与制剂共同审评 审批的原料/辅料/包材。 截至2025年中国中硼硅玻璃包材"A"类评审结果产品分布中,安瓿、输液瓶、注射剂瓶及其他分别为77 个、3个、116个和43个。 3、"A"评审结果国产数量多于进口 截至2025年中国中硼硅玻璃包材"A" ...
正川股份收盘上涨1.46%,滚动市盈率80.27倍,总市值34.61亿元
Sou Hu Cai Jing· 2025-08-05 11:12
Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Zhengchuan Co., which operates in the pharmaceutical packaging industry, specifically focusing on glass containers [1] - As of August 5, Zhengchuan Co. closed at 22.89 yuan, with a rolling PE ratio of 80.27 times, and a total market capitalization of 3.461 billion yuan [1] - The average PE ratio for the medical device industry is 54.24 times, with a median of 37.92 times, placing Zhengchuan Co. at the 101st position in the industry ranking [1][2] Group 2 - The latest quarterly report for Q1 2025 shows that Zhengchuan Co. achieved an operating revenue of 162 million yuan, a year-on-year decrease of 34.24%, and a net profit of 10.9141 million yuan, down 48.15% year-on-year, with a gross profit margin of 21.61% [1] - The company specializes in the research, production, and sales of pharmaceutical packaging materials, including borosilicate glass tubes and pre-filled syringes [1] - As of March 31, 2025, Zhengchuan Co. had 18,803 shareholders, a decrease of 638 from the previous count, with an average holding value of 352,800 yuan per shareholder [1]
正川股份股价下跌3.18% 盘中一度快速反弹
Jin Rong Jie· 2025-08-04 20:22
Group 1 - The stock price of Zhengchuan Co., Ltd. closed at 22.56 yuan on August 4, 2025, down 0.74 yuan or 3.18% from the previous trading day [1] - The opening price was 22.79 yuan, with a highest point of 23.19 yuan and a lowest point of 21.75 yuan, with a trading volume of 77,300 hands and a transaction amount of 174 million yuan [1] - On the morning of August 4, Zhengchuan Co., Ltd. experienced a quick rebound, with a rise of over 2% within 5 minutes, reaching a price of 22.8 yuan [1] Group 2 - Zhengchuan Co., Ltd. specializes in the research, production, and sales of pharmaceutical glass packaging materials, primarily used in the fields of biopharmaceuticals and vaccines [1] - The company operates in sectors including medical devices and the Chongqing region [1] - On August 4, the net outflow of main funds was 11.9955 million yuan, with a cumulative net outflow of 9.5609 million yuan over the past five days [1]
正川股份收盘下跌3.18%,滚动市盈率79.12倍,总市值34.11亿元
Sou Hu Cai Jing· 2025-08-04 11:53
Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Zhengchuan Co., which is currently facing a decline in stock price and profitability [1][2] - As of August 4, Zhengchuan Co. closed at 22.56 yuan, down 3.18%, with a rolling PE ratio of 79.12 times, significantly higher than the industry average of 54.32 times [1] - The company's total market capitalization is 3.411 billion yuan, ranking 99th in the medical device industry based on PE ratio [1][2] Group 2 - Zhengchuan Co. reported a revenue of 162 million yuan for Q1 2025, reflecting a year-on-year decrease of 34.24%, and a net profit of 10.91 million yuan, down 48.15% year-on-year [1] - The company's sales gross margin stands at 21.61% [1] - Zhengchuan Co. specializes in the research, production, and sales of pharmaceutical packaging materials, including borosilicate glass tubes and pre-filled syringes [1]
正川股份收盘下跌2.18%,滚动市盈率81.71倍,总市值35.23亿元
Sou Hu Cai Jing· 2025-08-01 12:22
Company Overview - Zhengchuan Co., Ltd. closed at 23.3 yuan, down 2.18%, with a rolling PE ratio of 81.71 times and a total market value of 3.523 billion yuan [1] - The company specializes in the research, production, and sales of pharmaceutical packaging materials, including borosilicate glass vials and sodium-calcium glass vials [1] - Zhengchuan is a member of the China Pharmaceutical Packaging Association and the National Packaging Standardization Technical Committee [1] Financial Performance - For Q1 2025, the company reported revenue of 162 million yuan, a year-on-year decrease of 34.24%, and a net profit of 10.9141 million yuan, down 48.15% [1] - The sales gross margin for the same period was 21.61% [1] Shareholder Information - As of March 31, 2025, the number of shareholders was 18,803, a decrease of 638 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical device industry is 53.65 times, with a median of 37.22 times, placing Zhengchuan at the 101st position in the industry ranking [1][2] - The industry includes various companies with lower PE ratios, such as Jiuan Medical at 11.01 times and Yingke Medical at 15.45 times [2]
正川股份收盘上涨6.62%,滚动市盈率83.53倍,总市值36.02亿元
Sou Hu Cai Jing· 2025-07-31 12:41
Group 1 - The core viewpoint of the news is that Zhengchuan Co., Ltd. has seen a significant increase in its stock price, closing at 23.82 yuan, up 6.62%, with a rolling PE ratio of 83.53, marking a new low in 697 days, and a total market value of 3.602 billion yuan [1] - The company operates in the pharmaceutical packaging materials sector, focusing on the research, production, and sales of medicinal glass tubes and other packaging materials, with key products including borosilicate glass tubes and pre-filled syringe components [1] - As of March 31, 2025, the number of shareholders in Zhengchuan Co., Ltd. is 18,803, a decrease of 638 from the previous count, with an average holding value of 352,800 yuan per shareholder [1] Group 2 - The latest financial results for the first quarter of 2025 show that the company achieved an operating income of 162 million yuan, a year-on-year decrease of 34.24%, and a net profit of 10.9141 million yuan, down 48.15%, with a gross profit margin of 21.61% [1] - In terms of industry comparison, the average PE ratio for the medical device sector is 54.89, while the median is 37.06, placing Zhengchuan Co., Ltd. at the 100th position in the industry ranking [2] - The company’s static PE ratio is 67.64, and its price-to-book ratio is 2.98, with a total market value of 3.602 billion yuan [2]